Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Allarity Therapeutics Inc (ALLR)

Allarity Therapeutics Inc (ALLR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,592
  • Shares Outstanding, K 15,802
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,520 K
  • EBIT $ -17 M
  • EBITDA $ -7 M
  • 60-Month Beta 0.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.23
  • Number of Estimates 1
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9702 +8.23%
on 12/23/25
1.3500 -22.22%
on 11/28/25
-0.1200 (-10.26%)
since 11/24/25
3-Month
0.9702 +8.23%
on 12/23/25
1.8000 -41.67%
on 10/10/25
-0.5800 (-35.58%)
since 09/24/25
52-Week
0.6138 +71.07%
on 04/09/25
2.3500 -55.32%
on 08/26/25
+0.0350 (+3.45%)
since 12/24/24

Most Recent Stories

More News
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among...

CVS : 79.12 (+1.38%)
EXAS : 101.54 (-0.05%)
ABBV : 229.89 (+0.48%)
RSLS : 15.68 (+22.50%)
ALLR : 1.0500 (unch)
Allarity Therapeutics Reports Extended Treatment Duration and Financial Strength to Advance Stenoparib for Ovarian Cancer

Allarity Therapeutics reports positive Phase 2 trial results for stenoparib in ovarian cancer and expands laboratory services.Quiver AI SummaryAllarity Therapeutics has reported significant progress in...

ALLR : 1.0500 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR). Such...

ALLR : 1.0500 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR). Such...

ALLR : 1.0500 (unch)
Allarity Therapeutics (NASDAQ: ALLR) Reports Early Success in Phase 2 Trial for Breast Cancer Drug IXEMPRA®

Allarity Therapeutics (NASDAQ: ALLR), a clinical-stage pharmaceutical company, recently announced preliminary results from its Phase 2 clinical trial assessing the

ALLR : 1.0500 (unch)
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies

New strategy aligns with ongoing shift in oncology standard-of-caretowards combination therapies Combination therapy focus expected to improve the...

ALLR : 1.0500 (unch)
Allarity Therapeutics Announces Executive Leadership Transition

  Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer,Joan Y. Brown, CPA, to Interim Chief Financial Officer Press release      ...

ALLR : 1.0500 (unch)
Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.

Cambridge, MA U.S.A. (June 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel...

ALLR : 1.0500 (unch)
Allarity Therapeutics Reports First Quarter 2022 Financial Results

Cambridge, MA U.S.A. (May 27, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel...

ALLR : 1.0500 (unch)
Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Cambridge, MA U.S.A. (May 18, 2022) — Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced today that its press release issued under the headline “Allarity...

ALLR : 1.0500 (unch)

Business Summary

Allarity Therapeutics Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel oncology therapeutics together with drug-specific DRP(R) companion diagnostics for personalized cancer care. Allarity Therapeutics Inc. is based in Cambridge, MA U.S.A.

See More

Key Turning Points

3rd Resistance Point 1.1533
2nd Resistance Point 1.1167
1st Resistance Point 1.0833
Last Price 1.0500
1st Support Level 1.0133
2nd Support Level 0.9767
3rd Support Level 0.9433

See More

52-Week High 2.3500
Fibonacci 61.8% 1.6868
Fibonacci 50% 1.4819
Fibonacci 38.2% 1.2770
Last Price 1.0500
52-Week Low 0.6138

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar